Delivery Order 1232SC18D0002-12234919F0003

This is a $26,650.70 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS) to Genewiz, LLC, a subsidiary of Azenta, Inc. The contract is for custom cloning and lentiviral preparation services to support the development of assays and therapeutics for NGYL1 disease within NCATS' Therapeutic Development Branch. The work includes gene cloning, lentiviral vector preparation, and generation of lentiviral particles at high titer. This contract has...

This firm fixed-price purchase order, valued at $14,607.70, was awarded by the National Institute of Child Health and Human Development (NICHD) to Genscript USA Inc. for gene synthesis and cloning services. The ultimate completion date is August 29, 2024. Genscript is a biotechnology company based in Piscataway, New Jersey that specializes in molecular biology products and services to support biomedical research and public health initiatives for various federal agencies, including the National...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $702,500 firm-fixed-price contract to Genscript USA Inc. to provide gene synthesis services in support of COVID-19 testing. Under the contract, Genscript will synthesize 150 genes and conduct 150 mutagenesis and 250 express cloning projects, as well as prepare 425 plasmids. These products and services will support the testing of COVID-19 antibody therapeutics, convalescent plasma, and vaccines...

Genscript USA Incorporated will provide gene synthesis services to the National Institutes of Health's National Institute of Allergy and Infectious Diseases under a $12,500 firm fixed price purchase order. The one-year contract was awarded on September 14, 2023 and runs through September 13, 2024. Genscript will deliver the gene synthesis work from its location in Piscataway, New Jersey. No subcontractors or additional context were provided regarding the specific research being supported under...

This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $3,182.40 firm fixed price delivery order is for gene synthesis services. Genscript specializes in providing customized DNA, antibodies, proteins, peptides, and other molecular biology products and services to support biomedical research and public health initiatives...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Genscript USA Inc., a biotechnology company, for "EXPRESS PLASMID PREPARATION, EXPRESS MUTAGENESIS TARGET AND CLONEARK PLASMID PREPARATION" services. The $149,984.10 contract has a completion date of September 13, 2022 and does not have a set-aside designation. Genscript has provided similar services to support...

The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $248,857.00 Firm Fixed Price purchase order to Genscript USA Inc., a biotechnology company, for the provision of "FAST GENE SYNTHESIS" services. The contract has an August 7, 2023 completion date and was awarded on August 8, 2022. Genscript is a for-profit organization that provides gene synthesis, gene editing, custom protein and antibody production, and other molecular biology services to...

This firm fixed-price purchase order for $18,204.88 was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Genscript USA Inc. to obtain cell lines utilizing CRISPR gene editing technology. Specifically, the contract calls for Genscript to generate knockout HEK293 and HepG2 cell lines of the MMAB and MUT genes to support studies for hereditary disorders of vitamin B12 and methylmalonic acid metabolism. No set-aside designation...

This is a $3,078,000.00 firm fixed-price contract awarded by the National Cancer Institute (NCI) to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of gene synthesis, peptide synthesis, and quality control analysis services to support the NCI Surgery Branch's clinical research efforts on mutation-reactive T-cells for the treatment of metastatic cancers. The contract has a 12-month base period with two 12-month option periods. There...

The Department of Health and Human Services' National Institutes of Health's National Institute of Child Health and Human Development awarded a $14,141.84 purchase order to Genscript USA Inc. for "OTHER FUNCTIONS - CUSTOMIZED GENE SYNTHESES" to be performed in Bethesda, Maryland between September 8-16, 2016. As a firm fixed price contract for customized gene synthesis services, Genscript will deliver specified genetic material to the NIH organization to support its biomedical...